Naoko Takebe to Interleukin-15
This is a "connection" page, showing publications Naoko Takebe has written about Interleukin-15.
Connection Strength
0.245
-
Phase 1 study evaluating the safety, preliminary efficacy, and pharmacodynamics of recombinant interleukin-15 in combination with nivolumab and ipilimumab in patients with refractory cancers. J Immunother Cancer. 2025 Dec 21; 13(12).
Score: 0.245